The Dow Jones Dives Alongside Johnson & Johnson

The Dow Jones Dives Alongside Johnson & Johnson

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

The markets are taking a step back from recent record highs today. As of 2:15 p.m. EST, the Dow Jones Industrial Average has lost more than 60 points, with most of its member stocks in the red.

Johnson & Johnson is among the Dow's worst performers today, as investors have pulled back from the stock's 33% year-to-date rise. Shares of the health care giant are down 1% to rank among the Dow's worst losers, but don't fret about the fall: Johnson & Johnson is still out-competing its toughest rivals where it matters most.

Johnson & Johnson's global profile
Sales have fallen off their fast-paced growth recently at Johnson & Johnson, as the company's third-quarter revenue pulled back from its year-to-date growth. For the quarter, the firm's sales grew by only 3.1% -- less than half the stellar 6.6% sales growth Johnson & Johnson recorded over the first nine months of 2013 in all. That's better than the Dow Jones' other big drugmakers, which have been dealing with the patent cliff and its related problems, but Johnson & Johnson investors expect consistency from this firm's breadth across the health care market.

Blame sluggish U.S. sales for that decline. The United States makes up around 45% of Johnson & Johnson's sales profile, but the region's revenue growth slumped to just 1.7% for the third quarter. That actually fell below the likes of rival Abbott Labs's for that time period; Abbott racked up 3.3% American sales growth. Take a look over the longer term, however, and Johnson & Johnson's outpacing its competitor, as Abbott's U.S. sales have fallen 1% over the last nine months.

Abbott's one of Johnson & Johnson's closest competitors, but since the company has spun off its branded pharmaceutical firm, it's not so much a potent growth engine as a broad and consistent play for investors. It shows up internationally as well, where Johnson & Johnson has its rival firmly beat.

J&J's European business has exploded this year despite the downturn in the region's economy. European sales have jumped 10.4% over the past nine months. Adding to Johnson & Johnson's global success, non-U.S. Western Hemisphere sales have climbed 5% over the first three quarters of the year. Abbott has posted respectable 3.4% sales growth outside of the U.S. overall through the same time period, but such growth slowed down to just more than 1% in the third quarter.

It's a good lead for Johnson & Johnson over its closest rival, but even J&J has room to improve. Its Asia-Pacific and Africa sales have failed to impress, gaining only 2.2% so far in 2013. Considering China's and India's health care potential and middle-class surge, it's pivotal that Johnson & Johnson push more strongly into those regions in the future.

How dividend stocks like Johnson & Johnson can reward your financial future
Johnson & Johnson and Abbott Labs are both solid dividend picks for any investors, but why are stocks like these so valuable in the long run?

Dividend stocks can make you rich. While they don't garner the notoriety of highflying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list of nine in this free report. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

The article The Dow Jones Dives Alongside Johnson & Johnson originally appeared on

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published